GlassScriptPhysician profile
David S Chung
NPI 1851362974
$5,122.41
in general payments reported to CMS, 2019-2025
26 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $84.79 · 2021: $367 · 2022: $806 · 2023: $755 · 2024: $719 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,247 · Travel and Lodging: $555 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,247.28 |
| Travel and Lodging | $554.93 |
| Education | $169.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $982.68 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $914.72 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Gilead Sciences, INC. | $607.21 | 2021-2025 | |
| Pfizer INC. | $554.33 | 2022-2025 | |
| Boston Scientific Corporation | $307.19 | 2019-2020 | |
| Echosens North America, INC. | $238.25 | 2019 | |
| Celgene Corporation | $233.51 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $162.13 | 2019-2025 | |
| Depuy Synthes Sales INC. | $145.12 | 2025 | Na |
| Cook Medical LLC | $128.57 | 2023 | Echotip |
| Intuitive Surgical, INC. | $127.69 | 2019 | |
| Covidien LP | $121.23 | 2019 | |
| Olympus America INC. | $115.15 | 2023-2025 | Disposable Distal Attachment, Endoclot Sis, Visiglide |
| Merck Sharp & Dohme LLC | $73.49 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.35 | 2022-2023 | Entyvio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $61.13 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.78 | 2024 | Trulance, Xifaxan |
| 3-D Matrix, INC. | $47.13 | 2024 | |
| Shionogi INC | $45.47 | 2019 | |
| Ardelyx, INC. | $30.17 | 2025 | Ibsrela |
| Genzyme Corporation | $24.10 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $20.00 | 2024 | Iqirvo |
| Stryker Corporation | $19.13 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.01 | 2024 | Voquezna |
| Ferring Pharmaceuticals INC. | $14.48 | 2023 | Rebyota |
| Madrigal Pharmaceuticals | $14.39 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.